Literature DB >> 20167696

Interlaboratory diagnostic validation of conformation-sensitive capillary electrophoresis for mutation scanning.

Christopher J Mattocks1, Gemma Watkins, Daniel Ward, Tom Janssens, Ermanno A J Bosgoed, Kim van der Donk, Marjolijn J Ligtenberg, Bruno Pot, Joop Theelen, Nicholas C P Cross, Hans Scheffer, Gert Matthijs.   

Abstract

BACKGROUND: Indirect alternatives to sequencing as a method for mutation scanning are of interest to diagnostic laboratories because they have the potential for considerable savings in both time and costs. Ideally, such methods should be simple, rapid, and highly sensitive, and they should be validated formally to a very high standard. Currently, most reported methods lack one or more of these characteristics. We describe the optimization and validation of conformation-sensitive capillary electrophoresis (CSCE) for diagnostic mutation scanning.
METHODS: We initially optimized the performance of CSCE with a systematic panel of plasmid-based controls. We then compared manual analysis by visual inspection with automated analysis by BioNumerics software (Applied Maths) in a blinded interlaboratory validation with 402 BRCA1 (breast cancer 1, early onset) and BRCA2 (breast cancer 1, early onset) variants previously characterized by Sanger sequencing.
RESULTS: With automated analysis, we demonstrated a sensitivity of >99% (95% CI), which is indistinguishable from the sensitivity for conventional sequencing by capillary electrophoresis. The 95% CI for specificity was 90%-93%; thus, CSCE greatly reduces the number of fragments that need to be sequenced to fully characterize variants. By manual analysis, the 95% CIs for sensitivity and specificity were 98.3%-99.4% and 93.1%-95.5%, respectively.
CONCLUSIONS: CSCE is amenable to a high degree of automation, and analyses can be multiplexed to increase both capacity and throughput. We conclude that once it is optimized, CSCE combined with analysis with BioNumerics software is a highly sensitive and cost-effective mutation-scanning technique suitable for routine genetic diagnostic analysis of heterozygous nucleotide substitutions, small insertions, and deletions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167696     DOI: 10.1373/clinchem.2009.135426

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

1.  Validation of an NGS Approach for Diagnostic BRCA1/BRCA2 Mutation Testing.

Authors:  Daniela Dacheva; Rumyana Dodova; Ivan Popov; Teodora Goranova; Atanaska Mitkova; Vanio Mitev; Radka Kaneva
Journal:  Mol Diagn Ther       Date:  2015-04       Impact factor: 4.074

2.  Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes.

Authors:  Lídia Feliubadaló; Adriana Lopez-Doriga; Ester Castellsagué; Jesús del Valle; Mireia Menéndez; Eva Tornero; Eva Montes; Raquel Cuesta; Carolina Gómez; Olga Campos; Marta Pineda; Sara González; Victor Moreno; Joan Brunet; Ignacio Blanco; Eduard Serra; Gabriel Capellá; Conxi Lázaro
Journal:  Eur J Hum Genet       Date:  2012-12-19       Impact factor: 4.246

3.  BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.

Authors:  Inmaculada de Juan; Sarai Palanca; Asunción Domenech; Lidia Feliubadaló; Ángel Segura; Ana Osorio; Isabel Chirivella; Miguel de la Hoya; Ana Beatriz Sánchez; Mar Infante; Isabel Tena; Orland Díez; Zaida Garcia-Casado; Ana Vega; Àlex Teulé; Alicia Barroso; Pedro Pérez; Mercedes Durán; Estela Carrasco; M José Juan-Fita; Rosa Murria; Marta Llop; Eva Barragan; Ángel Izquierdo; Javier Benítez; Trinidad Caldés; Dolores Salas; Pascual Bolufer
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

4.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

5.  Men seeking counselling in a Breast Cancer Risk Evaluation Clinic.

Authors:  Ana Catarina Freitas; Ana Opinião; Sofia Fragoso; Hugo Nunes; Madalena Santos; Ana Clara; Sandra Bento; Ana Luis; Jorge Silva; Cecília Moura; Bruno Filipe; Patrícia Machado; Sidónia Santos; Saudade André; Paula Rodrigues; Joana Parreira; Fátima Vaz
Journal:  Ecancermedicalscience       Date:  2018-01-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.